pRECIST: Guidelines for Response Criteria for Use in Trials Testing Therapeutics in Pancreatic Cancer.
New assessment guidelines designed specifically for pancreatic cancer trials address weaknesses in standard tumor measurement criteria.
This paper proposes pRECIST, a set of modified response criteria designed specifically for evaluating therapeutics in pancreatic cancer clinical trials. The guidelines address known limitations of standard RECIST criteria in pancreatic cancer assessment.
What the study was
- Study design
- Guideline/Consensus
- Population
- Pancreatic cancer clinical trial patients
- Category
- Treatment Innovation
- Maturity
- Validated
- Journal
- Pancreas
Why it surfaced
Novel trial response criteria for pancreatic cancer — directly implementable in clinical trials. Addresses real gap in trial design.
A plain-language summary of published research — not medical advice. Talk to a clinician about your own care.